Nov. 4, 2004 -- Taking Fosamax or estrogen for osteoporosis may help protect against knee
osteoarthritis, according to a new study.
Osteoarthritis is the most common type of arthritis in the U.S. It causes the breakdown of cartilage between
joints. Knee osteoarthritis is common and disabling in many older adults, causing pain, inflammation, and limited joint movement.
In osteoporosis, bones become progressively thin and porous, leading to an increased risk of fracture. It
affects more women than men, since women typically have smaller and lighter bones. Women also lose bone mass at an earlier
age and more quickly than men.
Medications to prevent or treat osteoporosis include Fosamax, Evista, and estrogen. They work by altering the cycle of bone formation and breakdown.
These drugs were recently studied by researchers including Laura Carbone, MD, MS, of the University of Tennessee
Health Center. Carbone and colleagues wanted to find out if these osteoporosis medications had benefits against knee osteoarthritis.
Study participants were about 800 white and black women who were around 75 years old, on average. The women
were enrolled in a national, long-term research program called the Health, Aging, and Body Composition Study.
Participants rated their knee pain and had MRI images and X-rays taken of their knees. Once a year, they also
brought in all of their medications -- including over-the-counter drugs and supplements -- for the researchers to record.
About 26% of the women were using osteoporosis drugs, including 125 on estrogen, 31 on Fosamax, and eight
on Evista. Estrogen had been used for the longest period of time: almost 14 years, on average, compared to a little less than
two years for Fosamax and Evista use.
Compared with participants who weren't taking osteoporosis medications, users of Fosamax and estrogen had
fewer osteoarthritis bone abnormalities in their knees, according to the MRI images. Fosamax, but not estrogen, was also associated
with reduced knee pain.
"Our study suggests that [Fosamax] and estrogen may protect against the development of bone abnormalities
associated with knee osteoarthritis, which may have a beneficial effect on the overall course of the disease," write the researchers
in the November issue of the journal Arthritis & Rheumatism.
Because few black women in the study took osteoporosis medications, the researchers can't promise that the
same results apply to that population. They also note that the relatively short-term use of Fosamax and Evista might have
an impact on the results of their study. They say that longer studies are needed to evaluate the potential of using these
drugs to treat or prevent osteoarthritis.
"Different relationships might be observed if the drugs had been taken for longer periods of time," they write,
calling for further studies on the topic.
Meanwhile, experts say you can do your bones a favor by getting regular exercise to strengthen muscles, tendons,
and ligaments that surround knee joints. They also recommend maintaining a normal healthy weight and getting enough calcium
(1,200 mg per day) and vitamin D for bone strength.
SOURCES: Carbone, L. Arthritis & Rheumatism, November
2004; vol 50: pp 3516-3525. WebMD Medical Reference from Healthwise: "Osteoporosis: Topic Overview." WebMD Medical Reference
from Healthwise: "Osteoporosis: What Increases Your Risk." News release, John Wiley & Sons, Inc.
BETTER TO TAKE ESTRONGEN, A DRUG WITH A
LONG TRACK HISTORY, WITH MANY OTHER SALIBUROUS EFFECTS, THEN SOME NO ONE THAT COULD TURN OUT TO BE ANOTHER VIOXX.--JK
FOSAMAX* (alendronate sodium) is a bisphosphonate that acts as a specific inhibitor of osteoclast-mediated bone resorption. Bisphosphonates are synthetic analogs of pyrophosphate that bind to the hydroxyapatite found in bone. Alendronate sodium is chemically described as (4-amino-1-hydroxybutylidene) bisphosphonic acid monosodium salt trihydrate. The empirical formula of alendronate sodium is C4H12NNaO7P2•3H2O and its formula weight is 325.12.
Alendronate sodium is a white, crystalline, nonhygroscopic powder. It is soluble in water, very slightly soluble in alcohol, and practically insoluble in chloroform. Tablets FOSAMAX for oral administration contain 6.53, 13.05, 45.68, 52.21 or 91.37 mg of alendronate monosodium salt trihydrate, which is the molar equivalent of 5, 10, 35, 40 and 70 mg, respectively, of free acid, and the following inactive ingredients: microcrystalline cellulose, anhydrous lactose, croscarmellose sodium, and magnesium stearate. Tablets FOSAMAX 10 mg also contain carnauba wax. Each bottle of the oral solution contains 91.35 mg of alendronate monosodium salt trihydrate, which is the molar equivalent to 70 mg of free acid. Each bottle also contains the following inactive ingredients: sodium citrate dihydrate and citric acid anhydrous as buffering agents, sodium saccharin, artificial raspberry flavor, and purified water. Added as preservatives are sodium propylparaben 0.0225% and sodium butylparaben 0.0075%.
EVISTA® (raloxifene hydrochloride) is a selective estrogen
receptor modulator (SERM) that belongs to the benzothiophene class of compounds.
The chemical designation is methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-[ 4-[ 2-( 1-piperidinyl) ethoxy] phenyl]-,
hydrochloride. Raloxifene hydrochloride (HCl) has the empirical formula C28H27NO4S • HCl, which corresponds to a molecular weight of 510.05. Raloxifene HCl is an off-white to pale-yellow solid that is very slightly soluble in water.
EVISTA is supplied in a tablet dosage form for oral administration. Each EVISTA tablet contains 60 mg of raloxifene HCl, which is the molar equivalent of 55.71 mg of free base. Inactive ingredients include anhydrous
lactose, carnauba wax, crospovidone, FD& C Blue No. 2 aluminum lake, hydroxypropyl methylcellulose, lactose monohydrate, magnesium stearate, modified pharmaceutical glaze, polyethylene glycol, polysorbate 80, povidone, propylene glycol, and titanium dioxide.